William Plovanic (Canaccord Genuity) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are William Plovanic's stock ratings?

About 56% of William's ratings were profitable over a one-year hold, with an average return of +6.3% per rating, measured by 13Foresight from historical prices.

Q: How is William ranked?

William Plovanic is ranked #1320 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/William Plovanic

William Plovanic

Canaccord Genuity

Wall Street Analyst

★★★☆☆

#1320

on 13Foresight · ranked by our own returns

51%

Success Rate

+8.5%

Average Return

19 of 37 calls profitable · -13.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 51% of William Plovanic's ratings turned a profit when each position was held for 2 year — averaging +8.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

129 Buy 11 Hold 0 Sell

William's Stock Coverage 37 ratings · 2026-06-24

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
AORT Artivion	Jun 16, 2026	BUY	Strong Buy +97.9% avg upside 8 analysts	$36.00 71.07% Upside	·
TMDX TransMedics Group	Jun 09, 2026	BUY	Strong Buy +56.6% avg upside 15 analysts	$124.00 59.91% Upside	+6.1%
PLSE Pulse Biosciences	Jun 04, 2026	BUY	Strong Buy +17.8% avg upside 5 analysts	$32.00 25.15% Upside	·
PEN Penumbra	Jun 02, 2026	HOLD	Buy +4.5% avg upside 23 analysts	$374.00 18.08% Upside	-0.8%
IRTC Irhythm Technologies	Jun 01, 2026	BUY	Strong Buy +56.7% avg upside 19 analysts	$152.00 45.92% Upside	·
BSX Boston Scientific	Jun 01, 2026	BUY	Strong Buy +74.0% avg upside 38 analysts	$70.00 55.59% Upside	-5.6%
DXCM Dexcom	May 19, 2026	BUY	Strong Buy +43.8% avg upside 32 analysts	$82.00 15.32% Upside	+2.9%
HTFL HeartFlow, Inc.	May 15, 2026	BUY	Strong Buy +7.0% avg upside 8 analysts	$37.00 7.35% Upside	+18.8%
TLSI TriSalus Life Sciences	May 13, 2026	BUY	Strong Buy +124.5% avg upside 8 analysts	$7.00 69.08% Upside	+0.4%
CBLL Ceribell, Inc.	May 12, 2026	BUY	Strong Buy +36.1% avg upside 8 analysts	$25.00 37.51% Upside	+9.8%
CVRX CVRx	May 12, 2026	BUY	Strong Buy +128.8% avg upside 9 analysts	$10.00 99.60% Upside	+15.9%
TNDM Tandem Diabetes Care	May 08, 2026	BUY	Buy +128.8% avg upside 29 analysts	$35.00 128.79% Upside	-3.9%
PODD Insulet	May 07, 2026	BUY	Strong Buy +82.4% avg upside 32 analysts	$249.00 73.51% Upside	-9.1%
ATEC Alphatec Holdings	May 06, 2026	BUY	Strong Buy +117.9% avg upside 22 analysts	$23.00 157.36% Upside	+15.7%
ATRC Atricure	May 06, 2026	BUY	Strong Buy +59.6% avg upside 12 analysts	$55.00 90.76% Upside	+0.4%
SYK Stryker	May 01, 2026	BUY	Strong Buy +23.9% avg upside 36 analysts	$400.00 30.22% Upside	+2.2%
LUNG Pulmonx	Apr 30, 2026	BUY	Strong Buy +322.3% avg upside 9 analysts	$5.00 296.74% Upside	+7.0%
EW Edwards Lifesciences	Apr 24, 2026	HOLD	Strong Buy +12.8% avg upside 34 analysts	$85.00 2.05% Downside	+3.0%
STIM Neuronetics	Apr 06, 2026	BUY	Strong Buy +391.6% avg upside 6 analysts	$3.00 138.13% Upside	-31.8%
SIBN SI-Bone	Jan 22, 2024	BUY	Strong Buy +59.5% avg upside 18 analysts	$25.00 54.68% Upside	-12.4%
GMED Globus Medical	Jan 22, 2024	BUY	Strong Buy +20.4% avg upside 24 analysts	$79.00 0.88% Upside	+68.9%
AXGN AxoGen	Dec 21, 2023	BUY	Strong Buy -25.8% avg upside 21 analysts	$15.00 66.39% Downside	+347.3%
ANGO AngioDynamics	Dec 21, 2023	BUY	Strong Buy +37.2% avg upside 9 analysts	$19.00 54.44% Upside	+72.1%
ZBH Zimmer Biomet Holdings	Dec 15, 2023	HOLD	Buy +28.0% avg upside 37 analysts	$131.00 49.04% Upside	-20.7%
BVS Bioventus	Dec 07, 2023	BUY	Strong Buy +35.6% avg upside 8 analysts	$7.00 20.77% Downside	+38.8%
SNN Smith & Nephew Snats	Nov 30, 2023	HOLD	Buy +13.4% avg upside 14 analysts	$32.00 7.35% Upside	+35.2%
ENOV Enovis	Nov 07, 2023	BUY	Strong Buy +226.1% avg upside 37 analysts	$65.00 201.52% Upside	-41.9%
STAA Staar Surgical	Sep 15, 2023	HOLD	Hold +16.3% avg upside 16 analysts	$43.00 50.05% Upside	-36.2%
MMSI Merit Medical Systems	Aug 28, 2023	HOLD	Strong Buy +35.8% avg upside 15 analysts	$70.00 5.06% Upside	+36.6%
AFIB Acutus Medical	Aug 08, 2023	HOLD	Sell +619899.9% avg upside 5 analysts	$0.74 739899.93% Upside	·
OCGN Ocugen	Feb 02, 2016	BUY	Strong Buy +578.9% avg upside 17 analysts	$8.00 522.49% Upside	-1.7%
MDXG MiMedx Group	Jan 11, 2016	BUY	Strong Buy +180.5% avg upside 17 analysts	$12.00 224.39% Upside	+65.0%
LFWD Lifeward	Nov 05, 2015	BUY	Strong Buy +4.3% avg upside 8 analysts	$16.00 128.55% Upside	-82.7%
GADS Gadsden Prop	Feb 02, 2015	HOLD	Buy +8999900.1% avg upside 5 analysts	—	·
LIVN LivaNova	Jun 05, 2014	BUY	Strong Buy +0.9% avg upside 14 analysts	$63.00 20.09% Downside	-30.1%
OFIX Orthofix Medical	Sep 09, 2011	BUY	Strong Buy +214.1% avg upside 15 analysts	$45.00 378.30% Upside	-31.9%
IART Integra Lifesciences	Jun 28, 2011	BUY	Buy +134.8% avg upside 21 analysts	—	-22.5%

🔒 32 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

William Plovanic — Frequently Asked Questions

How accurate are William Plovanic's stock ratings?

Based on the calls 13Foresight could measure, about 56% of William's ratings were profitable over a one-year hold, with an average return of +6.3% per rating, or -6.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is William ranked on 13Foresight?

William Plovanic is currently ranked #1320 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does William cover?

William most recently has ratings on AORT, TMDX, PLSE, PEN, IRTC, BSX, DXCM, HTFL, TLSI, CBLL, CVRX, TNDM and 25 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!